公司資料
RenovoRx 股價、新聞與催化劑
- 股票代碼:
- RNXT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.20 USD (-14.29%)
收盤價
最後更新: 2026年8月17日
41.1M USD
市值
股價為何變動
As of Aug 17, 2026, RNXT closed down 14.3% at $1.20. No new same-company headline was identified in the current news window.
公司概覽
Targeted Intra-Arterial Drug Delivery
RenovoRx develops a localized drug-delivery approach intended to concentrate therapy within solid tumors while reducing systemic exposure. Its Trans-Arterial Micro-Perfusion platform combines a device with a targeted treatment protocol.
RenovoCath
RenovoCath is an FDA-cleared dual-balloon infusion catheter designed to isolate a vascular segment and deliver therapy through the arterial wall. The device is commercially available to cancer centers as a stand-alone delivery product.
Broader Solid-Tumor Use
Although RenovoCath was initially used primarily in pancreatic cancer, physicians have begun applying the device in other solid tumors, including sarcoma. This creates a potential route to expand utilization beyond the lead clinical indication.
TIGeR-PaC
The Phase 3 TIGeR-PaC trial evaluates RenovoCath-mediated intra-arterial gemcitabine in locally advanced pancreatic cancer. Overall survival is the principal registrational objective, and successful results could support a future NDA.
未來催化劑
- Completion of the Phase 3 TIGeR-PaC trial in the first half of 2027.
- Topline results from TIGeR-PaC in the second half of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。